There is a strong trend toward improvement of medical practice through earlier, more selective or even individualised treatment with the help of innovative diagnostic procedures. More precise diagnosis and tailored treatment can help improve clinical outcomes, avoid side effects and contribute to overall cost savings. Innovative diagnostics are generating an ever increasing share of the total value creation in healthcare and open up new markets and investment possibilities.
Wellington believes that highly attractive opportunities exist for companies that deal with early diagnosis of life threatening diseases such as cancer, but also in the fields of monitoring chronic diseases, in point-of-care diagnosis, personalised medicine and predictive testing. A key driver of innovation in this connection is a detailed understanding of the underlying pathophysiology and interindividual / genetic differences and the use of molecular biology and highly sensitive and specific measurement technologies for the quantification of key disease markers and parameters.